BTIG raised the firm’s price target on GeneDx (WGS) to $115 from $95 and keeps a Buy rating on the shares. The shares are up roughly 40% after ...

BTIG analyst Ryan Zimmerman maintained a Hold rating on Medtronic (MDT – Research Report) today. The company’s shares opened today at ...

BTIG downgraded General Dynamics Corporation (NYSE:GD)to Neutral given the ongoing regulatory hurdles and supply chain disruptions that could hamper growth in 2025.

BTIG Research decreased their Q1 2025 earnings estimates for shares of Meritage Homes in a report issued on Tuesday, February ...

On Wednesday, BTIG analysts stood firm on their positive stance towards GeneDx (NASDAQ:WGS), reiterating a Buy rating and a $95.00 price target for the company's stock. With analyst targets ...

NEW YORK--(BUSINESS WIRE)--BTIG announced today that it will host its annual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Tuesday, February 11 through Wednesday ...

On Monday, BTIG analyst Andrew Harte maintained a Neutral rating on Global Payments Inc. (NYSE:GPN) stock, despite an approximate 11% increase in share value since the company's third-quarter 2024 ...

Oncocyte will host one-on-one meetings with interested investors. Investors attending the conference wishing to schedule a meeting are encouraged to contact BTIG to schedule.

Research analysts at BTIG Research reduced their Q4 2025 earnings estimates for shares of D.R. Horton in a research note issued to investors on Tuesday, January 28th. BTIG Research analyst C.

On Monday, BTIG analyst Andrew Harte maintained a Neutral rating on Global Payments Inc. (NYSE:GPN) stock, despite an approximate 11% increase in share value since the company's third-quarter 2024 ...

announced today that it will participate in the BTIG at Snowbird: MedTech, Digital Health, Life Science & Diagnostic Tools Conference, on Wednesday, February 12th. Rohit Ramchandani, CFO ...